Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

NCT02103478 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome
MDS

Interventions

DRUG: ASTX727 Dose Escalation
DRUG: ASTX727 Dose Confirmation
DRUG: ASTX727 Fixed-Dose Combination

Sponsor

Astex Pharmaceuticals, Inc.